Skip to content

Study · Randomized controlled trial · n = 43 · 2017

3 results

Intranasal oxytocin does not modulate jumping to conclusions in schizophrenia: Potential interactions with caudate volume and baseline social functioning.

Caravaggio F, Gerretsen P, Mar W, Chung JK, Plitman E, Nakajima S, Kim J, Iwata Y, Patel R, Chakravarty MM, Remington G, Graff-Guerrero A, Menon M

Psychoneuroendocrinology31 Mar 2017Cited by 9 (Europe PMC)

PMID28431278 (opens in a new tab)DOI10.1016/j.psyneuen.2017.03.020 (opens in a new tab)PepBankPUB-28431278
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In exploratory analyses in patients with schizophrenia, oxytocin was more likely to improve jumping to conclusions in those with lower baseline social functioning, but this did not survive correction for multiple comparisons.

    In plain wordsIn men with schizophrenia, oxytocin may have helped those with poorer social functioning, but this did not hold after statistical correction.

    Peptide
    Oxytocin
    Outcome
    IncreaseImprovement of jumping to conclusions by baseline social functioning
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Exploratory
    Outcome group
    Cognition and memory · Mental health and mood
    Studied dose
    50 IU · intranasalAs given in this study (human).

    Source sentences

    Summary
    Moreover, oxytocin was more likely to improve JTC in patients with lower baseline SF.
    3 context sentences
    Summary · context
    However, these exploratory findings did not survive correction for multiple comparisons.
    Summary · context
    Forty-three male, medicated SCZ patients (Mean Age: 40.81±11.44) and sixteen HCs (Mean Age: 30.38±9.85) participated in a double-blind, placebo-controlled, cross-over study.
    Summary · context
    Participants were randomized to receive either intranasal oxytocin (50IU in solution) or intranasal placebo (saline).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In male medicated patients with schizophrenia, intranasal oxytocin did not significantly change draws to decision versus placebo.

    In plain wordsIn men with schizophrenia, oxytocin did not change how much information they gathered before deciding, compared with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeDraws to decision (jumping to conclusions) in patients with schizophrenia
    Study

    n = 43

    Comparator
    Placebo
    Outcome group
    Cognition and memory · Mental health and mood
    Studied dose
    50 IU · intranasalAs given in this study (human).

    Measurements

    p value
    0.27
    patients

    Source sentences

    Summary
    Oxytocin did not significantly change DTD in patients (t(42)=-1.11, p=0.27)
    2 context sentences
    Summary · context
    Forty-three male, medicated SCZ patients (Mean Age: 40.81±11.44) and sixteen HCs (Mean Age: 30.38±9.85) participated in a double-blind, placebo-controlled, cross-over study.
    Summary · context
    Participants were randomized to receive either intranasal oxytocin (50IU in solution) or intranasal placebo (saline).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In healthy controls, intranasal oxytocin did not significantly change draws to decision versus placebo.

    In plain wordsIn healthy controls, oxytocin did not change how much information they gathered before deciding, compared with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeDraws to decision (jumping to conclusions) in healthy controls
    Study

    n = 16

    Comparator
    Placebo
    Outcome group
    Cognition and memory · Mental health and mood
    Studied dose
    50 IU · intranasalAs given in this study (human).

    Measurements

    p value
    0.55
    healthy controls

    Source sentences

    Summary
    nor in HCs (t(15)=-0.62, p=0.55)
    2 context sentences
    Summary · context
    Forty-three male, medicated SCZ patients (Mean Age: 40.81±11.44) and sixteen HCs (Mean Age: 30.38±9.85) participated in a double-blind, placebo-controlled, cross-over study.
    Summary · context
    Participants were randomized to receive either intranasal oxytocin (50IU in solution) or intranasal placebo (saline).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:49 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.